Go to ...

Nordens Ekonomi Norge

RSS Feed

21. februar 2019

Edison issues outlook on Atossa Genetics (ATOS)


Euroinvestor.com A/S Euroinvestor.com A/S


LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics’s (ATOS) endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data from its Phase I study on topical endoxifen in men, and it completed enrolment for its Phase II end..

More Stories From

Do NOT follow this link or you will be banned from the site!
Read previous post:
Issue of Equity

Worldwide Healthcare Trust Plc - Issue of Equity

Close